These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36157151)

  • 21. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD.
    Natarajan Y; Loomba R
    J Clin Exp Hepatol; 2022; 12(1):174-179. PubMed ID: 35068797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis.
    Bhati C; Idowu MO; Sanyal AJ; Rivera M; Driscoll C; Stravitz RT; Kohli DR; Matherly S; Puri P; Gilles H; Cotterell A; Levy M; Sterling RK; Luketic VA; Lee H; Sharma A; Siddiqui MS
    Transplantation; 2017 Aug; 101(8):1867-1874. PubMed ID: 28296807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis.
    Manka P; Bechmann L; Best J; Sydor S; Claridge LC; Coombes JD; Canbay A; Moeller L; Gerken G; Wedemeyer H; Syn WK
    Dig Dis Sci; 2019 Aug; 64(8):2351-2358. PubMed ID: 31155687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Hagström H; Elfwén O; Hultcrantz R; Stål P
    Gastroenterol Res Pract; 2018; 2018():1942648. PubMed ID: 30057598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation.
    Sourianarayanane A; Arikapudi S; McCullough AJ; Humar A
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):481-487. PubMed ID: 28253211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?
    Jain S; Thanage R; Panchal F; Rathi PM; Munshi R; Udgirkar SS; Contractor QQ; Chandnani SJ; Sujit NP; Debnath P; Singh A
    J Clin Exp Hepatol; 2021; 11(4):466-474. PubMed ID: 34276153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores.
    Wu Y; Yang X; Morris HL; Gurka MJ; Shenkman EA; Cusi K; Bril F; Donahoo WT
    JMIR Med Inform; 2022 Jun; 10(6):e36997. PubMed ID: 35666557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver Stiffness Measurement by Using Transient Elastography in Bangladeshi Patients with Type 2 Diabetes Mellitus and Ultrasonography-Diagnosed Nonalcoholic Fatty Liver Disease.
    Alam MS; Kamrul-Hasan ABM; Kalam ST; Rahman SMM; Hoque MI; Islam MB; Paul AK
    Diabetes Metab Syndr Obes; 2021; 14():3089-3096. PubMed ID: 34262313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in ultrasound elastography for nonalcoholic fatty liver disease.
    Yoneda M; Honda Y; Nogami A; Imajo K; Nakajima A
    J Med Ultrason (2001); 2020 Oct; 47(4):521-533. PubMed ID: 32748075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.
    Troelstra MA; Witjes JJ; van Dijk AM; Mak AL; Gurney-Champion O; Runge JH; Zwirs D; Stols-Gonçalves D; Zwinderman AH; Ten Wolde M; Monajemi H; Ramsoekh S; Sinkus R; van Delden OM; Beuers UH; Verheij J; Nieuwdorp M; Nederveen AJ; Holleboom AG
    J Magn Reson Imaging; 2021 Dec; 54(6):1937-1949. PubMed ID: 33991378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and risk factors of nonalcoholic fatty liver disease, high-risk nonalcoholic steatohepatitis, and fibrosis among lean United States adults: NHANES 2017-2020.
    Kalligeros M; Vassilopoulos S; Vassilopoulos A; Shehadeh F; Lazaridou I; Mylonakis E; Promrat K; Wands JR
    Ann Gastroenterol; 2023; 36(6):670-677. PubMed ID: 38023978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic Fatty Liver Disease after Liver Transplant.
    Shetty A; Giron F; Divatia MK; Ahmad MI; Kodali S; Victor D
    J Clin Transl Hepatol; 2021 Jun; 9(3):428-435. PubMed ID: 34221929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.